0R1D Stock Overview A clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sangamo Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sangamo Therapeutics Historical stock prices Current Share Price US$1.18 52 Week High US$3.18 52 Week Low US$0.30 Beta 1.3 1 Month Change -39.49% 3 Month Change 41.64% 1 Year Change 124.36% 3 Year Change -80.69% 5 Year Change -90.23% Change since IPO -89.78%
Recent News & Updates
Sangamo Therapeutics, Inc. Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain Nov 20
Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.59 loss in 3Q 2023) Nov 14
New major risk - Revenue and earnings growth Nov 14
Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
New major risk - Financial position Aug 09
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.66 loss in 2Q 2023) Aug 07 See more updates
Sangamo Therapeutics, Inc. Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain Nov 20
Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.59 loss in 3Q 2023) Nov 14
New major risk - Revenue and earnings growth Nov 14
Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
New major risk - Financial position Aug 09
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.66 loss in 2Q 2023) Aug 07
Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
New minor risk - Market cap size Jun 18
New major risk - Financial position May 13
Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024 May 10
First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023) May 10
Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03 Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq May 01
Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024 Apr 21
New minor risk - Market cap size Apr 19 Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million. Mar 25
Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million. Mar 22
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023 Mar 14
Full year 2023 earnings released: US$1.48 loss per share (vs US$1.25 loss in FY 2022) Mar 13 Sangamo Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920 Feb 07
Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial Dec 13 Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023 Nov 02
Sangamo Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 26
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy Oct 24
New minor risk - Market cap size Oct 05
New major risk - Financial position Aug 10
Second quarter 2023 earnings released: US$0.66 loss per share (vs US$0.29 loss in 2Q 2022) Aug 09
Sangamo Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Sangamo Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer May 17
First quarter 2023 earnings released: EPS: US$0.13 (vs US$0.30 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$1.25 loss per share (vs US$1.23 loss in FY 2021) Feb 24
Sangamo Therapeutics, Inc. Announces Directors Appointment Dec 21
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 3Q 2021) Nov 05
Sangamo Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Nine Patients Oct 12
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Five Longest Treated Patients Aug 31 Sangamo Therapeutics, Inc Announces Executive Changes Aug 10
Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.33 loss in 2Q 2021) Aug 05
Sangamo Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.32 loss in 1Q 2021) May 06
Sangamo Therapeutics, Inc. to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) May 03
High number of new and inexperienced directors Apr 27
Saira Ramasastry Decides Not to Stand for Re-Election as A Member of the Board of Directors of Sangamo Therapeutics, Inc Apr 03
Sangamo Therapeutics, Inc., Annual General Meeting, May 24, 2022 Apr 02
Sangamo Therapeutics, Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation Mar 30
Sangamo Therapeutics, Inc. Doses First Patient in Its Phase 1/2 STEADFAST Clinical Study Evaluating TX200 Mar 29
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26
Sangamo Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Patients with Fabry Disease Feb 08
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease Dec 13
Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.011 loss in 3Q 2020) Nov 05
Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.26 loss in 2Q 2020) Aug 08
First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.37 loss in 1Q 2020) May 06
Executive VP recently sold US$73k worth of stock Mar 27
Sangamo Therapeutics, Inc. Appoints Prathyusha Duraibabu as Principal Financial Officer Mar 18
Full year 2020 earnings released: US$0.90 loss per share (vs US$0.85 loss in FY 2019) Feb 26
Revenue misses expectations Feb 26
Sangamo Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
Executive VP & CFO has left the company Feb 03
Sangamo Therapeutics Appoints Rob Schott as Senior Vice President and Head of Development Feb 02 Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee, Effective February 1, 2021
Insider recently sold US$60k worth of stock Jan 02
Third quarter 2020 earnings released: US$0.011 loss per share Nov 07
Revenue beats expectations Nov 07
Sangamo Therapeutics, Inc. to Report Q3, 2020 Results on Nov 04, 2020 Oct 30
Pfizer Inc. and Sangamo Therapeutics, Inc. Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment Oct 08
Sangamo Therapeutics, Inc. Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019 Sep 29 Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.
First half earnings released Aug 11 Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from Russell Small Cap Comp Value Index Shareholder Returns 0R1D GB Biotechs GB Market 7D -6.4% -3.5% 0.3% 1Y 124.4% -23.5% 6.6%
See full shareholder returns
Return vs Industry: 0R1D exceeded the UK Biotechs industry which returned -23.5% over the past year.
Return vs Market: 0R1D exceeded the UK Market which returned 6.6% over the past year.
Price Volatility Is 0R1D's price volatile compared to industry and market? 0R1D volatility 0R1D Average Weekly Movement 27.9% Biotechs Industry Average Movement 9.6% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0R1D's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0R1D's weekly volatility has increased from 22% to 28% over the past year.
About the Company Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.
Show more Sangamo Therapeutics, Inc. Fundamentals Summary How do Sangamo Therapeutics's earnings and revenue compare to its market cap? 0R1D fundamental statistics Market cap US$253.51m Earnings (TTM ) -US$134.84m Revenue (TTM ) US$52.29m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0R1D income statement (TTM ) Revenue US$52.29m Cost of Revenue US$129.85m Gross Profit -US$77.56m Other Expenses US$57.28m Earnings -US$134.84m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.65 Gross Margin -148.33% Net Profit Margin -257.86% Debt/Equity Ratio 0%
How did 0R1D perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 19:13 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sangamo Therapeutics, Inc. is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Huidong Wang Barclays Gregory Harrison BofA Global Research Jonathan Aschoff Brean Capital
Show 21 more analysts 
